Abstract
Recent studies have implicated the involvement of Ca2+-dependent mechanisms, in particular, calcium/calmodulin-protein kinase II in nicotine-induced antinociception using the tail-flick test. The spinal cord was suggested as a possible site of this involvement. The present study was undertaken to investigate the hypothesis that the β2 nicotinic receptor subunit plays a central role in nicotine-induced spinal antinociception via calcium/calmodulin-dependent calmodulin protein kinase II activation. The antinociceptive effects of i.t. nicotine in the tail-flick test did not significantly differ in wild-type and α7 knockout (KO) animals but were lost in β2 knockout mice. When calcium/calmodulin-dependent calmodulin protein kinase II activity in the lumbar spinal cord after acute i.t. administration of nicotine was investigated in wild-type and β2 and α7 knockout mice, the increase in calcium/calmodulin-dependent calmodulin protein kinase II activity was not significant reduced in α7 KO mice but was eliminated in the β2 KO mice. In addition, L-type calcium channel blockers nimodipine and verapamil but not the N-methyl-d-aspartate antagonist MK-801 (dizocilpine maleate) blocked the increase in the kinase activity induced by nicotine. Taken together, these results are consistent with the hypothesis that increases in intracellular calcium result in activation of calcium-mediated second messengers in the spinal cord that play an important role in nicotine-induced antinociception as measured in the tail-flick test. Furthermore, our findings indicate that nicotinic stimulation of β2-containing acetylcholine nicotinic receptors in the spinal cord can activate calcium/calmodulin-dependent calmodulin protein kinase II and produce nicotinic analgesia, which may require L-type calcium voltage and gated channels but not the intervention of glutamatergic transmission.
Footnotes
-
This work was supported by National Institute on Drug Abuse Grants DA-12610 and DA-05274.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.111336.
-
ABBREVIATIONS: nAChR, acetylcholine nicotinic receptor; NMDA, N-methyl-d-aspartate; MK-801, dizocilpine maleate; α-BGTX, α-bungarotoxin; MLA, methyllycaconitine; %MPE, % maximal possible effect; LCC, L-type calcium channel; CREB, cAMP response element-binding protein.
- Received July 21, 2006.
- Accepted October 12, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|